Hypertension:服药依从性对肾脏去神经支配疗效的影响!

2017-03-08 xing.T MedSci原创

由此可见,随着时间的推移,药物治疗的依从性变化较为常见,并且对治疗估计影响相当大。在随机试验中,强烈建议在随访期间对服药依从性进行客观评估。

以导管为基础的肾脏去神经支配(RDN)作为顽固性高血压治疗手段的随机试验在降低血压的效应上显示出了相互矛盾的结果。在这个病人组中药物治疗的依从性一般,其可能是这些相互矛盾的结果的重要驱动因素。近日,心血管权威杂志Hypertension上针对这一问题发表了一篇研究文章。

SYMPATHY是在荷兰顽固性高血压患者中进行的前瞻性开放标签的多中心试验。该研究的主要结果是6个月的日间动态收缩压的变化情况。患者在常规治疗的基础上被随机分配进行RDN治疗。研究人员在研究之初和随访中对参与者抗高血压药物的依从性进行了评估,在采集血液样本的同时进行血压测量。患者和医生均对依从性进行评估。

主要分析显示接受RDN治疗的顽固性高血压患者(n=95)和对照者(n=44)之间6个月白天收缩压的平均差异为2mmHg(95%可信区间为-6.1至10.2mmHg),有利于对照者。在80%的患者中,相比于处方的药物治疗数量,检测到的药物数量较少,并且在随访期间依从性改变了31%。在那些在随访期间有稳定依从性的患者中,平均白天收缩压在接受RDN治疗的患者和对照者之间的平均差异为-3.3mmHg(-13.7至7.2mmHg),有利于接受RDN治疗的患者。RDN作为抗高血压治疗的手段并不优于常规治疗。当患者对监测不知情的情况下,药物治疗的客观评估显示服药依从性极差。

由此可见,随着时间的推移,药物治疗的依从性变化较为常见,并且对治疗估计影响相当大。在随机试验中,强烈建议在随访期间对服药依从性进行客观评估。

原始出处:

Rosa L. de Jager, et al. Impact of Medication Adherence on the Effect of Renal Denervation The SYMPATHY Trial.Hypertension. 2017. https://doi.org/10.1161/HYPERTENSIONAHA.116.08818

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1726307, encodeId=fd281e2630747, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Feb 16 14:19:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038595, encodeId=e182203859577, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed May 17 18:19:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319265, encodeId=9682131926590, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Mar 10 12:19:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501127, encodeId=e51e150112e0a, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Mar 10 12:19:00 CST 2017, time=2017-03-10, status=1, ipAttribution=)]
    2018-02-16 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1726307, encodeId=fd281e2630747, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Feb 16 14:19:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038595, encodeId=e182203859577, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed May 17 18:19:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319265, encodeId=9682131926590, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Mar 10 12:19:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501127, encodeId=e51e150112e0a, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Mar 10 12:19:00 CST 2017, time=2017-03-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1726307, encodeId=fd281e2630747, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Feb 16 14:19:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038595, encodeId=e182203859577, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed May 17 18:19:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319265, encodeId=9682131926590, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Mar 10 12:19:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501127, encodeId=e51e150112e0a, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Mar 10 12:19:00 CST 2017, time=2017-03-10, status=1, ipAttribution=)]
    2017-03-10 fyxzlh
  4. [GetPortalCommentsPageByObjectIdResponse(id=1726307, encodeId=fd281e2630747, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Feb 16 14:19:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038595, encodeId=e182203859577, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed May 17 18:19:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319265, encodeId=9682131926590, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Mar 10 12:19:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501127, encodeId=e51e150112e0a, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Mar 10 12:19:00 CST 2017, time=2017-03-10, status=1, ipAttribution=)]

相关资讯

Heart:电话随访明显改善支架置入后患者服药依从性

  加拿大学者的一项研究表明,对药物洗脱支架(DES)置入后患者采取简单的4次电话回访可明显改善其1年的服药依从性,这一简单的干预方式也可显著改善双联抗血小板治疗(DAT)的持久性。相关论文2013年2月23日在线发表于《心脏》(heart)杂志。   该研究共纳入300例DES置入后的患者,将其随机分为干预组和对照组。为加强患者服药依从性,对干预组患者进行4次的电话随访,时间分别为DES

高血压疫苗的是是非非

根据最新在线发表在Hypertension杂志上的研究显示,治疗高血压的潜力疫苗或有一天能发挥降低血压效果长达半年。这个研究最终可能提供一种新的高血压替代治疗方法,或许以后谁也不会需要靠吃药维持日常血压水平。 日本最新研究:DNA疫苗或降低血压长达半年 关于疫苗的研究范围最近已经从传染病扩大到慢性疾病,包括阿尔茨海默病、血脂异常、高血压。日本大阪大学的研究人员设计了一种DNA疫苗,